1. Regulatory Highlights
2. European Medicines Agency.Update on review of recalled valsartan medicines: preliminary assessment of possible risk to patients. August2018. Accessed September 3 2023.https://www.ema.europa.eu/en/news/update-review-recalled-valsartan-medicines-preliminary-assessment-possible-risk-patients
3. US Food and Drug Administration.Control of Nitrosamine Impurities in Human Drugs Guidance for Industry. February2021. Accessed September 3 2023.https://www.fda.gov/media/141720/download?attachment
4. Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products
5. European Medicines Agency.Ranitidine‐containing medicinal products. European Commission final decision. Accessed October 24 2023.https://www.ema.europa.eu/en/medicines/human/referrals/ranitidine-containing-medicinal-products